Yesterday I graduated from
@BrighamGI fellowship, and today I get to celebrate my first @NEJM publication. Feeling very grateful, very lucky, and very excited for what’s next. 🎓📄✨
🏆 Editor's Pick of the Month #ACGCRJ
Kwashiorkor Mimicking Portal Hypertensive Ascites After Bariatric Surgery
https://t.co/ldDyJZd3Ch
Not all high-SAAG ascites is portal hypertension: kwashiorkor after bariatric surgery can be a convincing mimic.
Exciting time in MASLD, lots of emerging compounds.
One to know => survodutide
➡️ GLPRA/Glucagon agonist
➡️ unlike GLP, liver has glucagon receptors so survodutide acts directly on the liver
➡️ SYNCHRONIZE-MASLD 2026
- MASLD pts defined by MRI (~90%) likely with F0-2
- survodutide met co-primary endpoints
1. 84% had =>30% reduction in liver fat
Congratulations to our incredible Program Director, Dr. Molly Perencevich, on receiving the @MassGenBrigham Graduate Medical Education Outstanding Program Director Award, selected from among all training programs throughout the MGB system🏆
Thank you, Molly, for your unwavering dedication to fellow education, mentorship, and exceptional leadership. So well deserved! 👏🎉
Yesterday I graduated from
@BrighamGI fellowship, and today I get to celebrate my first @NEJM publication. Feeling very grateful, very lucky, and very excited for what’s next. 🎓📄✨
Graduated from the Harvard Chan School of Public Health
@HarvardChanSPH
today! Also found out I’ll be the next
@AGA_CGH
editorial fellow 😀 feeling so incredibly excited for this opportunity 🧬 @BrighamGI
Andres Duarte-Rojo, MD, is a part of a team leading Northwestern Medicine's efforts to enhance survival of patients who are preparing for liver transplantation through a personalized at-home program that assesses mobility, exercise, diet and more. This program prepares patients for transplantation and aims to reduce post-transplant complications and hospital admissions. Read the full article: https://t.co/Zky6hcBZZX
Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new treatments.
A new study found that GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity: https://t.co/MhUTBf9G7h